Resalis Therapeutics
Riccardo Panella is currently working as an Associate Professor at the Center for RNA Medicine, where Riccardo investigates the role of microRNA in metabolic disease and develops new therapeutic strategies. Riccardo is also the Founder and CSO at Resalis Therapeutics Srl, focusing on developing anti-miR compounds for liver diseases, metabolic disorders, and cancer. Riccardo previously worked at the Desert Research Institute and Beth Israel Deaconess Medical Center, conducting research on cancer, metabolism, and genetics. Riccardo holds a PhD in Oncology and Cancer Biology, as well as a Mini-MBA from Harvard Business School.
This person is not in any teams
This person is not in any offices
Resalis Therapeutics
1 followers
Resalis Therapeutics’ transformative metabolic disease approach targets a master regulator of key pathways underlying obesity and fatty liver disease. The company is applying its unique understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of hepatic steatosis. Building on robust preclinical evidence, Resalis will rapidly bring RES-010 into clinical trials for a range of metabolic disorders.